Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-02-07

AUTHORS

Christine Lebrun-Frenay, Antoine Moulignier, Charles Pierrot-Deseilligny, Rabah Benrabah, Thibault Moreau, Catherine Lubetzki, Françoise Monchecourt,

ABSTRACT

The benefits provided by disease-modifying treatments in multiple sclerosis have been demonstrated in clinical trials, but the extent to which they can be extrapolated to everyday care is less clear, as are the long-term benefits of treatment. The objective of this prospective observational cohort study performed in France was to evaluate the effectiveness and safety of glatiramer acetate in patients with relapsing–remitting multiple sclerosis over a 5-year period. All neurologists in France were invited to participate and enroll adult patients starting a first treatment with brand glatiramer acetate 20 mg. Given the observational nature of the study, no fixed study visits were imposed; consultations took place according to the investigator’s normal practice. Occurrence of disease exacerbations and adverse events was documented and neurological disability evaluated with the EDSS at each consultation. Overall, 852 patients were analysable and 269 took glatiramer acetate continuously for 5 years. Median treatment duration was 3.4 years. Principal reasons for discontinuation were inadequate efficacy (38.9%), local tolerability (22.6%) and personal convenience (21.3%). Age, employment status, baseline EDSS score and number of previous exacerbations were variables associated with treatment persistence. The annualised exacerbation rate (5 years) was 0.41 [95% CI 0.39–0.44]; 316 patients (37.2%) remained exacerbation-free throughout. The risk of confirmed disability worsening (5 years) was 43.8% [95% CI 39.9–47.9%]. The most frequent adverse drug reactions were local injection site reactions (584 patients; 68.5%) and systemic immediate post-injection reactions (168 patients; 19.7%). Overall, these findings are consistent with those of previous clinical trials. More... »

PAGES

888-901

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00415-019-09211-5

DOI

http://dx.doi.org/10.1007/s00415-019-09211-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111981033

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30730008


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disability Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glatiramer Acetate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Longitudinal Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medication Adherence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Sclerosis, Relapsing-Remitting", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service de Neurologie, CRCSEP, H\u00f4pital Pasteur 2, Universit\u00e9 Nice Cote d\u2019Azur, CS 51069, 30, voie Romaine, 06001, Nice Cedex 1, France", 
          "id": "http://www.grid.ac/institutes/grid.31151.37", 
          "name": [
            "Service de Neurologie, CRCSEP, H\u00f4pital Pasteur 2, Universit\u00e9 Nice Cote d\u2019Azur, CS 51069, 30, voie Romaine, 06001, Nice Cedex 1, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lebrun-Frenay", 
        "givenName": "Christine", 
        "id": "sg:person.0615205403.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615205403.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fondation Ophtalmologique A. de Rothschild, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417888.a", 
          "name": [
            "Fondation Ophtalmologique A. de Rothschild, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moulignier", 
        "givenName": "Antoine", 
        "id": "sg:person.01356471366.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356471366.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "D\u00e9partement de Neurologie, H\u00f4pital de la Salp\u00eatri\u00e8re, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "D\u00e9partement de Neurologie, H\u00f4pital de la Salp\u00eatri\u00e8re, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pierrot-Deseilligny", 
        "givenName": "Charles", 
        "id": "sg:person.012514627357.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012514627357.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier National d\u2019Ophtalmologie des Quinze-Vingts, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.415610.7", 
          "name": [
            "Centre Hospitalier National d\u2019Ophtalmologie des Quinze-Vingts, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Benrabah", 
        "givenName": "Rabah", 
        "id": "sg:person.0642642700.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642642700.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de Neurologie, Centre Hospitalier Universitaire de Dijon-Bourgogne, Dijon, France", 
          "id": "http://www.grid.ac/institutes/grid.31151.37", 
          "name": [
            "Service de Neurologie, Centre Hospitalier Universitaire de Dijon-Bourgogne, Dijon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moreau", 
        "givenName": "Thibault", 
        "id": "sg:person.016116176044.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016116176044.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "D\u00e9partement des Maladies du Syst\u00e8me Nerveux, H\u00f4pital de la Salp\u00eatri\u00e8re, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "D\u00e9partement des Maladies du Syst\u00e8me Nerveux, H\u00f4pital de la Salp\u00eatri\u00e8re, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lubetzki", 
        "givenName": "Catherine", 
        "id": "sg:person.01234255566.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234255566.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Teva Sant\u00e9, La D\u00e9fense, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Teva Sant\u00e9, La D\u00e9fense, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Monchecourt", 
        "givenName": "Fran\u00e7oise", 
        "id": "sg:person.01251407612.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251407612.32"
        ], 
        "type": "Person"
      }, 
      {}
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00415-005-0748-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032132939", 
          "https://doi.org/10.1007/s00415-005-0748-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10072-008-0939-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038535999", 
          "https://doi.org/10.1007/s10072-008-0939-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-02-07", 
    "datePublishedReg": "2019-02-07", 
    "description": "The benefits provided by disease-modifying treatments in multiple sclerosis have been demonstrated in clinical trials, but the extent to which they can be extrapolated to everyday care is less clear, as are the long-term benefits of treatment. The objective of this prospective observational cohort study performed in France was to evaluate the effectiveness and safety of glatiramer acetate in patients with relapsing\u2013remitting multiple sclerosis over a 5-year period. All neurologists in France were invited to participate and enroll adult patients starting a first treatment with brand glatiramer acetate 20\u00a0mg. Given the observational nature of the study, no fixed study visits were imposed; consultations took place according to the investigator\u2019s normal practice. Occurrence of disease exacerbations and adverse events was documented and neurological disability evaluated with the EDSS at each consultation. Overall, 852 patients were analysable and 269 took glatiramer acetate continuously for 5\u00a0years. Median treatment duration was 3.4\u00a0years. Principal reasons for discontinuation were inadequate efficacy (38.9%), local tolerability (22.6%) and personal convenience (21.3%). Age, employment status, baseline EDSS score and number of previous exacerbations were variables associated with treatment persistence. The annualised exacerbation rate (5\u00a0years) was 0.41 [95% CI 0.39\u20130.44]; 316 patients (37.2%) remained exacerbation-free throughout. The risk of confirmed disability worsening (5\u00a0years) was 43.8% [95% CI 39.9\u201347.9%]. The most frequent adverse drug reactions were local injection site reactions (584 patients; 68.5%) and systemic immediate post-injection reactions (168 patients; 19.7%). Overall, these findings are consistent with those of previous clinical trials.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00415-019-09211-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1014525", 
        "issn": [
          "0340-5354", 
          "1432-1459"
        ], 
        "name": "Journal of Neurology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "266"
      }
    ], 
    "keywords": [
      "glatiramer acetate", 
      "multiple sclerosis", 
      "clinical trials", 
      "immediate post-injection reactions", 
      "relapsing-remitting multiple sclerosis", 
      "prospective observational cohort study", 
      "post-injection reactions", 
      "frequent adverse drug reactions", 
      "Five-year outcomes", 
      "disease-modifying treatments", 
      "local injection site reactions", 
      "glatiramer acetate 20", 
      "baseline EDSS score", 
      "median treatment duration", 
      "observational cohort study", 
      "injection site reactions", 
      "previous clinical trials", 
      "adverse drug reactions", 
      "long-term benefits", 
      "previous exacerbations", 
      "disease exacerbation", 
      "exacerbation rate", 
      "EDSS score", 
      "nationwide cohort", 
      "cohort study", 
      "adverse events", 
      "treatment persistence", 
      "adult patients", 
      "neurological disability", 
      "local tolerability", 
      "site reactions", 
      "inadequate efficacy", 
      "study visit", 
      "drug reactions", 
      "observational nature", 
      "treatment duration", 
      "first treatment", 
      "patients", 
      "sclerosis", 
      "everyday care", 
      "exacerbation", 
      "treatment", 
      "employment status", 
      "trials", 
      "disability", 
      "acetate 20", 
      "consultation", 
      "normal practice", 
      "tolerability", 
      "EDSS", 
      "discontinuation", 
      "neurologists", 
      "years", 
      "cohort", 
      "visits", 
      "care", 
      "efficacy", 
      "age", 
      "outcomes", 
      "risk", 
      "scores", 
      "study", 
      "principal reason", 
      "duration", 
      "benefits", 
      "safety", 
      "status", 
      "personal convenience", 
      "acetate", 
      "findings", 
      "period", 
      "persistence", 
      "occurrence", 
      "rate", 
      "events", 
      "objective", 
      "practice", 
      "reaction", 
      "extent", 
      "throughout", 
      "France", 
      "variables", 
      "number", 
      "reasons", 
      "effectiveness", 
      "convenience", 
      "place", 
      "nature", 
      "Observatory", 
      "brand glatiramer acetate 20", 
      "investigator\u2019s normal practice", 
      "exacerbation-free throughout", 
      "systemic immediate post-injection reactions", 
      "copaxone observatory"
    ], 
    "name": "Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France", 
    "pagination": "888-901", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111981033"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00415-019-09211-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30730008"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00415-019-09211-5", 
      "https://app.dimensions.ai/details/publication/pub.1111981033"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_831.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00415-019-09211-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00415-019-09211-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00415-019-09211-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00415-019-09211-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00415-019-09211-5'


 

This table displays all metadata directly associated to this object as RDF triples.

276 TRIPLES      22 PREDICATES      135 URIs      125 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00415-019-09211-5 schema:about N07bb09e6898d4db284f66ef32731334d
2 N179a4ab900104e5bafa21c56526a59bf
3 N2867643d714e45e1acb041d485f02d43
4 N29080e949c3a44a4be0c640f1c98fd43
5 N2a1a084c8afd4b4fb7f125eac934af2f
6 N2b5720f087124d1494b181c2759a2c8b
7 N33d708bec0ff42448ccf6e8c08361200
8 N82e68b7161f94e6b9b02ceaba9c84d68
9 Nac6c4b07bfe74976a905db8a41179d94
10 Ncc70ee08b2294a3688ec649d1c16ea5e
11 Nda279f766d7c4d18b062bc675cf2cffc
12 Neb3c316c6aa743dbbaced251bd7c9cc9
13 Nebbd0d4042c142ab86c098a954ac6227
14 anzsrc-for:11
15 anzsrc-for:1103
16 schema:author N31d96fcbed70459e9ecfa5ae4fd5824b
17 schema:citation sg:pub.10.1007/s00415-005-0748-5
18 sg:pub.10.1007/s10072-008-0939-9
19 schema:datePublished 2019-02-07
20 schema:datePublishedReg 2019-02-07
21 schema:description The benefits provided by disease-modifying treatments in multiple sclerosis have been demonstrated in clinical trials, but the extent to which they can be extrapolated to everyday care is less clear, as are the long-term benefits of treatment. The objective of this prospective observational cohort study performed in France was to evaluate the effectiveness and safety of glatiramer acetate in patients with relapsing–remitting multiple sclerosis over a 5-year period. All neurologists in France were invited to participate and enroll adult patients starting a first treatment with brand glatiramer acetate 20 mg. Given the observational nature of the study, no fixed study visits were imposed; consultations took place according to the investigator’s normal practice. Occurrence of disease exacerbations and adverse events was documented and neurological disability evaluated with the EDSS at each consultation. Overall, 852 patients were analysable and 269 took glatiramer acetate continuously for 5 years. Median treatment duration was 3.4 years. Principal reasons for discontinuation were inadequate efficacy (38.9%), local tolerability (22.6%) and personal convenience (21.3%). Age, employment status, baseline EDSS score and number of previous exacerbations were variables associated with treatment persistence. The annualised exacerbation rate (5 years) was 0.41 [95% CI 0.39–0.44]; 316 patients (37.2%) remained exacerbation-free throughout. The risk of confirmed disability worsening (5 years) was 43.8% [95% CI 39.9–47.9%]. The most frequent adverse drug reactions were local injection site reactions (584 patients; 68.5%) and systemic immediate post-injection reactions (168 patients; 19.7%). Overall, these findings are consistent with those of previous clinical trials.
22 schema:genre article
23 schema:inLanguage en
24 schema:isAccessibleForFree true
25 schema:isPartOf N12a83e2e5ab14032b907a903dc0cf54d
26 N6d0e9fc394a14f49a0e45eafab58f658
27 sg:journal.1014525
28 schema:keywords EDSS
29 EDSS score
30 Five-year outcomes
31 France
32 Observatory
33 acetate
34 acetate 20
35 adult patients
36 adverse drug reactions
37 adverse events
38 age
39 baseline EDSS score
40 benefits
41 brand glatiramer acetate 20
42 care
43 clinical trials
44 cohort
45 cohort study
46 consultation
47 convenience
48 copaxone observatory
49 disability
50 discontinuation
51 disease exacerbation
52 disease-modifying treatments
53 drug reactions
54 duration
55 effectiveness
56 efficacy
57 employment status
58 events
59 everyday care
60 exacerbation
61 exacerbation rate
62 exacerbation-free throughout
63 extent
64 findings
65 first treatment
66 frequent adverse drug reactions
67 glatiramer acetate
68 glatiramer acetate 20
69 immediate post-injection reactions
70 inadequate efficacy
71 injection site reactions
72 investigator’s normal practice
73 local injection site reactions
74 local tolerability
75 long-term benefits
76 median treatment duration
77 multiple sclerosis
78 nationwide cohort
79 nature
80 neurological disability
81 neurologists
82 normal practice
83 number
84 objective
85 observational cohort study
86 observational nature
87 occurrence
88 outcomes
89 patients
90 period
91 persistence
92 personal convenience
93 place
94 post-injection reactions
95 practice
96 previous clinical trials
97 previous exacerbations
98 principal reason
99 prospective observational cohort study
100 rate
101 reaction
102 reasons
103 relapsing-remitting multiple sclerosis
104 risk
105 safety
106 sclerosis
107 scores
108 site reactions
109 status
110 study
111 study visit
112 systemic immediate post-injection reactions
113 throughout
114 tolerability
115 treatment
116 treatment duration
117 treatment persistence
118 trials
119 variables
120 visits
121 years
122 schema:name Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France
123 schema:pagination 888-901
124 schema:productId N3a6e555865aa4c718b0c6dba6feff2d8
125 N4bcb6e55ee9d46ba8d8409dc584685e2
126 Ndb28fbb728f145bab2bb11b3a4efaeb4
127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111981033
128 https://doi.org/10.1007/s00415-019-09211-5
129 schema:sdDatePublished 2021-11-01T18:37
130 schema:sdLicense https://scigraph.springernature.com/explorer/license/
131 schema:sdPublisher N984d568c16944e8f99aff7804ad84457
132 schema:url https://doi.org/10.1007/s00415-019-09211-5
133 sgo:license sg:explorer/license/
134 sgo:sdDataset articles
135 rdf:type schema:ScholarlyArticle
136 N03daca5df34146ee9a9787fc496209d4 rdf:first N9a2bdcce73474dc0b8871c4c651adbd4
137 rdf:rest rdf:nil
138 N07bb09e6898d4db284f66ef32731334d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Treatment Outcome
140 rdf:type schema:DefinedTerm
141 N12a83e2e5ab14032b907a903dc0cf54d schema:issueNumber 4
142 rdf:type schema:PublicationIssue
143 N179a4ab900104e5bafa21c56526a59bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Immunosuppressive Agents
145 rdf:type schema:DefinedTerm
146 N2867643d714e45e1acb041d485f02d43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Medication Adherence
148 rdf:type schema:DefinedTerm
149 N29080e949c3a44a4be0c640f1c98fd43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Longitudinal Studies
151 rdf:type schema:DefinedTerm
152 N2a1a084c8afd4b4fb7f125eac934af2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Multiple Sclerosis, Relapsing-Remitting
154 rdf:type schema:DefinedTerm
155 N2b5720f087124d1494b181c2759a2c8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Prospective Studies
157 rdf:type schema:DefinedTerm
158 N31d96fcbed70459e9ecfa5ae4fd5824b rdf:first sg:person.0615205403.51
159 rdf:rest Na82961165e2746ddb29646059f592a34
160 N33d708bec0ff42448ccf6e8c08361200 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Adult
162 rdf:type schema:DefinedTerm
163 N3a6e555865aa4c718b0c6dba6feff2d8 schema:name pubmed_id
164 schema:value 30730008
165 rdf:type schema:PropertyValue
166 N4bcb6e55ee9d46ba8d8409dc584685e2 schema:name dimensions_id
167 schema:value pub.1111981033
168 rdf:type schema:PropertyValue
169 N682aa1cae33d421e8bb0e7b23e5a0432 rdf:first sg:person.01251407612.32
170 rdf:rest N03daca5df34146ee9a9787fc496209d4
171 N6d0e9fc394a14f49a0e45eafab58f658 schema:volumeNumber 266
172 rdf:type schema:PublicationVolume
173 N7a3f508584d34369ab04bfdd7e0b6ce1 rdf:first sg:person.016116176044.55
174 rdf:rest Ncfd8c234d7eb4638b32aabcc494500f1
175 N8273e202a6574435911d33ac99ed7c69 rdf:first sg:person.0642642700.48
176 rdf:rest N7a3f508584d34369ab04bfdd7e0b6ce1
177 N82e68b7161f94e6b9b02ceaba9c84d68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Humans
179 rdf:type schema:DefinedTerm
180 N984d568c16944e8f99aff7804ad84457 schema:name Springer Nature - SN SciGraph project
181 rdf:type schema:Organization
182 Na82961165e2746ddb29646059f592a34 rdf:first sg:person.01356471366.57
183 rdf:rest Nae9967c478674374b85a1ba23527ca4c
184 Nac6c4b07bfe74976a905db8a41179d94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Follow-Up Studies
186 rdf:type schema:DefinedTerm
187 Nae9967c478674374b85a1ba23527ca4c rdf:first sg:person.012514627357.89
188 rdf:rest N8273e202a6574435911d33ac99ed7c69
189 Ncc70ee08b2294a3688ec649d1c16ea5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Disability Evaluation
191 rdf:type schema:DefinedTerm
192 Ncfd8c234d7eb4638b32aabcc494500f1 rdf:first sg:person.01234255566.28
193 rdf:rest N682aa1cae33d421e8bb0e7b23e5a0432
194 Nda279f766d7c4d18b062bc675cf2cffc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Glatiramer Acetate
196 rdf:type schema:DefinedTerm
197 Ndb28fbb728f145bab2bb11b3a4efaeb4 schema:name doi
198 schema:value 10.1007/s00415-019-09211-5
199 rdf:type schema:PropertyValue
200 Neb3c316c6aa743dbbaced251bd7c9cc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Male
202 rdf:type schema:DefinedTerm
203 Nebbd0d4042c142ab86c098a954ac6227 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Female
205 rdf:type schema:DefinedTerm
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
210 schema:name Clinical Sciences
211 rdf:type schema:DefinedTerm
212 sg:journal.1014525 schema:issn 0340-5354
213 1432-1459
214 schema:name Journal of Neurology
215 schema:publisher Springer Nature
216 rdf:type schema:Periodical
217 sg:person.01234255566.28 schema:affiliation grid-institutes:grid.411439.a
218 schema:familyName Lubetzki
219 schema:givenName Catherine
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234255566.28
221 rdf:type schema:Person
222 sg:person.01251407612.32 schema:affiliation grid-institutes:None
223 schema:familyName Monchecourt
224 schema:givenName Françoise
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251407612.32
226 rdf:type schema:Person
227 sg:person.012514627357.89 schema:affiliation grid-institutes:grid.411439.a
228 schema:familyName Pierrot-Deseilligny
229 schema:givenName Charles
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012514627357.89
231 rdf:type schema:Person
232 sg:person.01356471366.57 schema:affiliation grid-institutes:grid.417888.a
233 schema:familyName Moulignier
234 schema:givenName Antoine
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356471366.57
236 rdf:type schema:Person
237 sg:person.016116176044.55 schema:affiliation grid-institutes:grid.31151.37
238 schema:familyName Moreau
239 schema:givenName Thibault
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016116176044.55
241 rdf:type schema:Person
242 sg:person.0615205403.51 schema:affiliation grid-institutes:grid.31151.37
243 schema:familyName Lebrun-Frenay
244 schema:givenName Christine
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615205403.51
246 rdf:type schema:Person
247 sg:person.0642642700.48 schema:affiliation grid-institutes:grid.415610.7
248 schema:familyName Benrabah
249 schema:givenName Rabah
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642642700.48
251 rdf:type schema:Person
252 sg:pub.10.1007/s00415-005-0748-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032132939
253 https://doi.org/10.1007/s00415-005-0748-5
254 rdf:type schema:CreativeWork
255 sg:pub.10.1007/s10072-008-0939-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038535999
256 https://doi.org/10.1007/s10072-008-0939-9
257 rdf:type schema:CreativeWork
258 grid-institutes:None schema:alternateName Teva Santé, La Défense, France
259 schema:name Teva Santé, La Défense, France
260 rdf:type schema:Organization
261 grid-institutes:grid.31151.37 schema:alternateName Service de Neurologie, CRCSEP, Hôpital Pasteur 2, Université Nice Cote d’Azur, CS 51069, 30, voie Romaine, 06001, Nice Cedex 1, France
262 Service de Neurologie, Centre Hospitalier Universitaire de Dijon-Bourgogne, Dijon, France
263 schema:name Service de Neurologie, CRCSEP, Hôpital Pasteur 2, Université Nice Cote d’Azur, CS 51069, 30, voie Romaine, 06001, Nice Cedex 1, France
264 Service de Neurologie, Centre Hospitalier Universitaire de Dijon-Bourgogne, Dijon, France
265 rdf:type schema:Organization
266 grid-institutes:grid.411439.a schema:alternateName Département de Neurologie, Hôpital de la Salpêtrière, Paris, France
267 Département des Maladies du Système Nerveux, Hôpital de la Salpêtrière, Paris, France
268 schema:name Département de Neurologie, Hôpital de la Salpêtrière, Paris, France
269 Département des Maladies du Système Nerveux, Hôpital de la Salpêtrière, Paris, France
270 rdf:type schema:Organization
271 grid-institutes:grid.415610.7 schema:alternateName Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, France
272 schema:name Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, France
273 rdf:type schema:Organization
274 grid-institutes:grid.417888.a schema:alternateName Fondation Ophtalmologique A. de Rothschild, Paris, France
275 schema:name Fondation Ophtalmologique A. de Rothschild, Paris, France
276 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...